

2017 Annual Meeting | September 14-17 | Deerhurst Skyline Resort | Huntsville, Ontario


DIAGNOSTIC SLIDE SEMINAR: PART 1 RENAL TUMOUR BIOPSY CASES


Dr. Andrew J. Evans MD, PhD, FACP, FRCPC Consultant in Genitourinary Pathology University Health Network, Toronto, ON


Case 1


43 year-old female, incidentally found 1.5 cm right cystic renal mass

CT Scan: Cystic Right Renal Mass










AMACR +'ve CK 7 –'ve



Histologic Differential

- Cystic nephroma
- MEST/REST
- Oncocytoma with cystic elements
- Tubulocystic carcinoma

Diagnosis

Kidney: Right needle core biopsy:

- Cystic neoplasm with features suggestive of tubulocystic carcinoma. See comment.

Comment

The biopsy consists of fragmented cores of renal parenchyma, paucicellular fibrous stroma and a fragment of skeletal muscle. The background kidney is within normal limits. The fragments of fibrous stroma are consistent in appearance with a cystic lesion as per the supplied clinical history. The cystic spaces are lined by a single layer of plump cuboidal cells with slightly irregular nuclei and visible nucleoli, deeply eosinophilic cytoplasm and focal "hobnail" morphology. Psammomatous calcification is focally identified. No ovarian-type stroma is noted in the sampled tissue. No papillary structures or aggregates of clear cells are identified. Immunohistochemical staining shows the cuboidal lining cells to be positive for AMACR and negative for CK7.


Taken together, the features are consistent with the biopsy having sampled a cystic neoplasm. The differential diagnosis lies between tubulocystic carcinoma, cystic nephroma, mixed epithelial stromal tumour (MEST) and papillary renal cell carcinoma. While the amount of lesional tissue that has been sampled is quite limited, the H&E morphology and immunohistochemical profile described above are in keeping with a diagnosis of tubulocystic carcinoma. It should be recognized that there are inherent limitations associated with biopsy findings in the setting of cystic lesions. As such, histologic examination of the completely excised lesion would be required to confirm the above interpretation.


Tubulocystic carcinoma is regarded as low-grade malignant renal tumour. See the reference below for details on the clinicopathologic and molecular characteristics of this entity.


Reference:


Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Amin MB, MacLennan GT, Gupta R, Grignon D, Paraf F, Vieillefond A, Paner GP, Stovsky M, Young AN, Srigley JR, Cheville JC. Am J Surg Pathol 2009; 33(3): 384-92.

Partial Nephrectomy











Tubulocystic Carcinoma of the Kidney Clinicopathologic Analysis of 31 Cases of a Distinctive Rare Subtype of Renal Cell Carcinoma

Mahul B. Amin, MD,* Gregory T. MacLennan, MD,† Ruta Gupta, MD,* David Grignon, MD,‡ Francois Paraf, MD, PhD,§ Annick Vieillefond, MD, Gladell P. Paner, MD,* Mark Stovsky, MD, MBA, FACS,† Andrew N. Young, MD, PhD,¶ John R. Srigley, MD,# and John C. Cheville, MD**

(Am J Surg Pathol 2009;33:384-392)





Tubulocystic Carcinoma of the Kidney Clinicopathologic and Molecular Characterization


Ximing J. Yang, MD, PhD,*† Ming Zhou, MD, PhD,‡ Ondrej Hes, MD, PhD,§ Steven Shen, MD, PhD,|| Rongshan Li, MD, PhD,¶ Jose Lopez, MD,# Rajal B. Shah, MD,** Yu Yang, MD, PhD,†† Shang-Tian Chuang, DO,† Fan Lin, MD, PhD,‡‡ Maria M. Tretiakova, MD, PhD,§§ Eric J. Kort, MD,|||| and Bin Tean Teh, MD, PhD||||


(Am J Surg Pathol 2008;32:177–187)


- 13 cases
 - age range 36-94 years
 - M:F = 3.3:1
 - 10/13 pT1a (< 4 cm, kidney confined)
 - indolent course
 - 1/13 with lymph node metastases
- 5/13 associated with separate papillary RCC or papillary adenoma(s)
 - lack of trisomy 7 or 17

Case 2

46 year-old female, 2.0 cm incidentally found solid renal mass







Differential Diagnosis

- Papillary renal cell carcinoma, Type 1
- Epithelial-predominant adult Wilm's tumour
- Metanephric adenoma
- Metanephric adenofibroma

Immunohistochemistry

TABLE 4. Solid PRCC Versus Metanephric Adenoma Versus Wilms Tumor					
	CK7	AMACR	WT-1	CD57	
Solid papillary	Positive	Positive	Negative	Negative	
Metanephric adenoma	Negative or isolated cells	Negative	Positive, nuclear	Positive	
Wilms	Negative or isolated cells	Negative	Positive, nuclear	Negative	

Best Practices Recommendations in the Application of Immunohistochemistry in the Kidney Tumors Report From the International Society of Urologic Pathology Consensus Conference

Metanephric Adenoma

- Benign neoplasm
- Female predominance (2:1)
- Young children to elderly (median age 50 years)
- 10% present with polycythemia
- Typically 3-6 cm
- Calcification can be extensive
- Highly cellular, tightly packed small uniform acini (<u>+</u> elongated branching tubules)
- 50% with papillary structures
- Mitotic figures rare/absent


Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma

Stephanie N Kinney¹, John N Eble¹, Ondrej Hes², Sean R Williamson³, David J Grignon¹, Mingsheng Wang¹, Shaobo Zhang¹, Lee Ann Baldrige¹, Guido Martignoni⁴, Matteo Brunelli⁴, Lisha Wang⁵, Eva Comperat⁶, Rong Fan¹, Rodolfo Montironi⁷, Gregory T MacLennan⁸ and Liang Cheng¹

Modern Pathology (2015) 28, 1236-1248;

Antibody	Staining characteristics ^a	$\begin{array}{l} \mbox{Metanephric adenoma,} \\ \mbox{n} = 35^{\rm b} \ (\%) \end{array}$	Papillary renal cell carcinoma, n = 15 ^c (%)	Epithelial-predominant nephroblastoma, n = 20 (%)
WT1	Negative	0	15 (100)	0
	Focal	0	0	0
	Intermediate	3 (9)	0	2 (10)
	Diffuse	32 (91)	0	18 (90)
AMACR	Negative	34 (97)	0	20 (100)
	Focal	1 (3)	0	0
	Intermediate	0	0	0
	Diffuse	0	15 (100)	0
CK7	Negative	35 (100)	1 (7)	19 (95)
	Focal	0	0	0
	Intermediate	0	0	1 (5)
	Diffuse	0	14 (93)	0
CD57	Negative	0	14 (93)	4 (20)
	Focal	0	1 (7)	10 (50)
	Intermediate	0	0	2 (10)
	Diffuse	35 (100)	0	4 (20)


Table 3 Summary of immunohistochemical staining properties in metanephric adenoma, papillary renal cell carcinoma, and epithelialpredominant nephroblastoma



^aScoring: Diffuse >50%, intermediate 26-50%, focal 1-25%, negative <1%. ^bTwo tumors were reclassified as papillary renal cell carcinoma and were excluded from analysis with metanephric adenomas. "The two reclassified tumors were analyzed in the papillary renal cell carcinoma category.

Case 3

74 year-old female, gross hematuria and 5.4 cm renal mass



Tumours That Infiltrate Renal Parenchyma

- Collecting duct/medullary carcinoma
- Urothelial carcinoma
- Lymphoma
- Metastatic carcinoma
 - ≻ lung
 - breast
 - ≽ gyne PAX-8
 - head and neck



Infiltrative Tumours: Diagnostic Approach

- History other known cancer
- Radiology tumour location in the kidney
- Immunohistochemistry
 - ≻ PAX-8
 - ➢ GATA-3
 - ≻ p63
 - ➢ 34βΕ12
 - ≻ CK19
 - others as appropriate based on history, morphology, etc

Case 3: Immunohistochemistry

Positive

- CK7
- p63
- GATA3
- HMWK (34βE12)

Negative

- PAX8
- CK20
- GCDFP-15
- ER
- Mammoglobin

Case 3: Diagnosis

Diagnosis

Needle biopsy of kidney (left renal mass): - Invasive high-grade urothelial carcinoma. See comment.

Comment

Sections show cores of renal parenchyma that are extensively infiltrated by high-grade poorly differentiated carcinoma. Fragments of necrotic tissue are also present. The tumour cells have pleomorphic, hyperchromatic nuclei with some cells having prominent nucleoli. The cells are arranged in solid sheets as well as nests and cords within desmoplastic stroma. The tumour shows marked infiltration in between glomeruli and benign renal tubules. On immunohistochemical staining, the tumour cells are positive for CK7, GATA 3 and p63 and show weak patchy positivity with high molecular weight cytokeratin. They are negative for PAX-8, CK20, ER, GCDFP-15 and mammoglobin. The history of breast cancer supplied with the biopsy is acknowledged. Metastatic carcinoma was considered in the histologic differential diagnosis for this biopsy, however the H&E morphology and immunophenotype of the tumour is most consistent with high-grade urothelial carcinoma.




Fig. 7 – Renal tumour biopsies containing carcinoma with an infiltrative growth pattern. (A) Carcinoma infiltrating in between renal tubules and glomeruli in a patient with a solitary small renal mass and no history of a prior malignancy. (B) This tumour was positive for PAX-8. A biopsy diagnosis of *renal cell carcinoma* consistent with collecting carcinoma was given. (C) Another example of carcinoma infiltrating in between renal tubules and glomeruli in a patient with a solitary small renal mass and previous history adenocarcinoma of lung. (D) This tumour was positive for TTF-1 and the biopsy was reported as *metastatic adenocarcinoma* consistent with lung primary.

Collecting Duct Carcinoma


Metastatic NSC Lung Carcinoma


Collecting Duct Carcinoma

- A difficult definitive diagnosis on biopsy
- Nephrectomy criteria:
 - 1. Medullary tumour
 - 2. Mostly tubular morphology
 - 3. Infiltrative growth
 - 4. High-grade cytological features
 - 5. Desmoplastic stroma
 - 6. Absence of other RCC subtypes or urothelial carcinoma

Case 4

68 year-old male, 2.5 cm incidentally found left renal mass





Renal Tumours with Oncocytic/Eosinophilic Cytoplasm

Table 2 – Tumours characterized by cells with oncocytic or eosinophilic cytoplasm.

Usual

Issue

Oncocytoma Chromophobe renal cell carcinoma, eosinophilc variant Hybrid oncocytic-chromophobe tumours Clear cell renal cell carcinoma with eosinophilic cytoplasm (usually high grade) Papillary renal cell carcinoma with oncocytic features Papillary renal cell carcinoma, Type 2 Tubulocystic renal cell carcinoma Follicular thyroid-like carcinoma Acquired cystic kidney disease associated renal cell carcinoma Renal tumours associated with SDH-B mutations Epithelioid angiomyolipoma MiTF family translocation renal cell carcinoma Renal cell carcinoma of any histologic type with rhabdoid features

Expanded Differential

SEMINARS IN DIAGNOSTIC PATHOLOGY 32 (2015) 184-195

Categorizing renal oncocytic neoplasms on core needle biopsy: a morphologic and immunophenotypic study of 144 cases with clinical follow-up¹ Megan A. Alderman MD^a, Stephanie Daignault MS^a, J. Stuart Wolf Jr. MD^b, Ganesh S. Palapattu MD^b, Alon Z. Weizer MD^b, Khaled S. Hafez MB, BCh^b, Lakshmi P. Kunju MD^{a,*,1}, Angela J. Wu MD^{a,1}

^aDepartment of Pathology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA ^bDepartment of Urology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA





Fig. 1 Morphologic features included A, nested architecture, edematous stroma, binucleation (red arrow), and degenerative type atypia (black arrow) and B, tubular architecture; these features were present in many of the favor oncocytoma biopsies. Features which would support a diagnosis of favor RCC included C, extensive sheet-like architecture and cells with flocculent to clear cytoplasm (inset, arrows). Do, extensive papillary architecture with associated foamy macrophages; E, nuclear pleomorphism and enlarged hyperchromatic nuclei; and F, extensive flocculent cytoplasm, prominent cell borders, and raisinoid nuclei (arrows) (hematoxylin and cosin; original magnification A-C; ×4, C inset: ×20, D-F; v10).



Human Pathology (2016) 55, 1-10


CrossMark

U of M Diagnostic Terminology

- Oncocytic/eosinophilic renal neoplasm -
 - 1. favour oncocytoma
 - 2. cannot exclude renal cell carcinoma
 - 3. favour renal cell carcinoma

H&E Features Classifier

Nested Architecture	0	Nested Architecture			
Clearcells	0	Raisinoid nuclei	0		
Prominent cell borders	o	Clear cells	o		
Raisinoid nuclei	0	Edematous stroma	0		
Nuclear grade	0	Prominent cell borders	0		
Dense granular cytoplasm	o	Nuclear grade	0		
Papillary architecture	0	Flocculent cytoplasm	0		
Foam y macrophages	0	Papillary architecture	0		
Edematous stroma	0	Nuclear pleomorphism	o		
Nuclear pleomorphism	o	Foamy macrophages	0		
Sheetlike architecture	0	Sheetlike architecture	0		
Flocculent cytoplasm	0	Tubules	0		
Mitoses	0	Degenerative atypia	0		
Degenerative atypia	0	Prominent nucleoli	0		
Necrosis	0	Binucleation	0		
Tubules	0	Mitoses	0		
Prominent nucleoli	0	Dense granular cytoplasm	0		
Binucleation	0	Necrosis	0		
	L _I I I I I		4-1-1-1		
	0 10 20 30 Mean Decrease Accuracy		0 2 4 6 8 Mean Decrease Gini		



ISUP Panel: Tumours With Oncocytic Features


TABLE 5. Tumors With Oncocytic Features*

	CD117	CK7	Ksp-cadherin	HMB-45	Cathepsin-K
Oncocytoma	Positive, membranous	Negative	Positive	Negative	Negative
Chromophobe RCC, eosinophilic	Positive, membranous	Positive but variable	+/-Positive	Negative	Negative
Oncocytic PRCC	Negative	Positive but focal	Not known	Negative	Unknown
Oncocytic AML	Negative	Negative	Negative	Positive, focal	Negative

Other Abs said to be differentially expressed on oncocytomas and chromophobe RCC.

Positive in oncocytoma, negative in chromophobe: S100A1.

*Hale colloidal iron: Although a histochemical rather than an IHC stain, it can be useful in differentiating chromophobe carcinoma (cytoplasmic granular staining) from oncocytoma (negative or luminal staining). However, this is a technically demanding stain and reliability is laboratory-dependent.




CK 7


Arch Pathol Lab Med April 2012 Selected Common Diagnostic Problems in Urologic Pathology

Perspectives From a Large Consult Service in Genitourinary Pathology

Fadi Brimo, MD; Jonathan I. Epstein, MD

ONCOCYTOMA VERSUS CHROMOPHOBE RENAL CELL CARCINOMA






CK 7







The distinction ultimately comes down H&E morphology

Figure 3. A, Classic low-power appearance of oncocytoma with nests of eosinophilic cells in a fibromysolid background. B, Nuclear features in chromophole renal cell acricitoma (OhRCC with imegular nothces (strow) and some nuclei with binucleation and perinuckar halos. C, Solid pattern of oncocytoma. Note the uniform, round nuclei of oncocytoma compared with the nuclei in ChRCC D, Oncocytoma composed of numerous oncollas. E, Central scar of oncocytoma with agentaria scar of ancocytoma with a cluster of cells with degrad nuclei and provinent single and oncollas. E, Central scar of oncocytoma with a cluster of cells with degrad nuclei and provinent avail and nuclei. Call Solito Call and Solito Call and a cluster of cells with degrad nuclei and provinent arbita scar of ancocytoma with a cluster of cells with degrad nuclei and provinent arbita scar of ancocytoma on figural magnitudications X7104, X801B and FL, X401CL, and X201D, FL, and GL.




Figure 2. Waterfall plot demonstrating overall change in size (cm) from baseline to last imaging for oncocytoma (blue) and chromophobe RCC (orange).

Biopsy Cohort (2003-2014):

Figure 1. Study flow chart

- 79 oncocytic renal neoplasms (2/2 surgically confirmed oncocytoma)
- 14 chromophobe RCC (6/6 surgically confirmed)
- no metastases or tumour-related death in either group


Renal Tumour Biopsy: Barriers to Adoption

Survey of Canadian urologists (Richard 2017):


- Results do not change management (53%)
- Risk of false-negative or non-diagnostic biopsy (64%)
- "Neoplasm consistent with oncocytoma"
 a frequently stated reason to avoid biopsies


How to Address the Problem


 Establish an ancillary test to help confirm a biopsy diagnosis of oncocytoma - a <u>benign</u> tumour



Copy Number Variation Assay







The purpose of the CNV/methylation assay is to confirm the biopsy diagnosis of a benign tumour!

CNV-Plot:

Not an Oncocytoma Any other CNV plot interpreted as evidence the tumour is <u>not</u> an oncocytoma

Justification for CNV Approach

The American Journal of Pathology, Vol. 180, No. 6, June 2012 Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.ajpath.2012.01.044

Tumorigenesis and Neoplastic Progression

Renal Cell Neoplasms Contain Shared Tumor Type–Specific Copy Number Variations

John M. Krill-Burger,* Maureen A. Lyons,*[†] Lori A. Kelly,*[†] Christin M. Sciulli,*[†] Patricia Petrosko,*[†] Uma R. Chandran,^{†‡} Michael D. Kubal,[§] Sheldon I. Bastacky,*[†] Anil V. Parwani,*^{†‡} Rajiv Dhir,*^{†‡} and William A. LaFramboise*^{†‡}

Prom the Departments of Pathology* and Biomedical Informatics,[‡] University of Pittsburgh, Pittsburgh, Pennsylvania; the University of Pittsburgh Cancer Institute,[†] Pittsburgh, Pennsylvania; and Life Technologies,[§] Carlsbad, California

Affymatrix Genome-Wide Human SNP Array 6.0

- > 906.600 SNP's
- > 946,000 non-polymorphic probes




Figure 3. The location and frequency of CNVs in samples chromophole (A), clear cell (0), oncocytoma (C), papillary (type 1(D), and paplithary (type 2.00). The abstease is clusided into chromosomes delineated horizontally in line with the p am of the chromosomes to the led and the qurm to the right. Copy number game (amplifications, red) are the chromosomes to the led and uses, Copy number losses (deletions, blue) are indicated by negative values, which correspond to the percentage of samples containing the average values within each subclassification contain significant CNVs comptoing at least 30% of the chromosome.

Illustrative Case


- 68 year-old female
- Poor renal function
- 5.1 cm left renal mass on U/S November 2012
- Left renal mass biopsy January 2013

 consistent with oncocytoma
- Surveillance with serial imaging
- Liver mass biopsy November 2014

 metastatic carcinoma consistent with renal primary
- Autopsy December 1, 2014
 - post-mortem interval 7 days (expired 25/11/2014)


Left Renal Mass Biopsy







Oncocytic renal neoplasm consistent with oncocytoma


Biopsy of Liver Mass







Immunoprofile AE1/AE3 +'ve PAX-8 +'ve AMACR +'ve CK7 –'ve









Final Diagnosis – papillary renal cell carcinoma, NOS (most likely Type 2) with oncocytoma-like, glandular, solid and papillary areas

OPEN

Oncocytoma-Like Renal Tumor With Transformation Toward High-Grade Oncocytic Carcinoma

A Unique Case With Morphologic, Immunohistochemical, and Genomic Characterization

Sahussapont J. Sirintrapun, MD, Kim R. Geisinger, MD, Adela Cimic, MD, Anthony Snow, MD, Jill Hagenkord, MD, Federico Monzon, MD, Benjamin L. Legendre Jr, PhD, Anatole Ghazalpour, PhD, Ryan P. Bender, PhD, and Zoran Gatalica, MD, DSc

Medicine • Volume 93, Number 15, October 2014

- 74 year-old man
- 11 cm right renal mass
- Enlarged aortocaval lymph nodes
- Lung nodules
- "Oncocytic carcinoma"
 - 30% bland oncocytoma-like
 - No genomic changes in the bland area
 - 17p loss in carcinoma area (FLN – BHD)




FIGURE 1. (A) FNA of the aortocaval lymph node (20× objective), (3) Benign oncocytoma-like region of the renal tumor (20× objective). (C) High-grade oncocytic carcinoma region of the renal tumor (20× objective). (D) Aortocaval lymph node with metastatic tumor (10× objective). FNA = fine needle aspirate.




FIGURE 2. (A) Virtual karyotype using SNP-based array analysis. (B) Magnification of the heterozygous deletion in 17p that houses FLCN at 17p11.2. FLCN=folliculin (Birt-Hogg-Dubé protein).

Case 5

55 year-old male, 2.8 cm incidentally found left renal mass

"Clear cell" renal cell carcinoma.....

not so clear anymore

Renal Tumours With Clear Cytoplasm


- Conventional clear cell RCC
- Papillary RCC with "clear cell" areas
- Clear cell papillary RCC
- Chromophobe RCC
- Epithelioid angiomyolipoma
- MiTF-associated RCC (Xp11/TFE3, TFEB)

ISUP Panel: Tumours With Clear Cells/Papillary Components


TABLE 2. Tumors Composed Predominantly of "Clear" Cells									
Tumor Type	CA IX	CK7	CD117	Cathepsin-K	HMB-45				
Clear cell RCC	Positive, diffuse membranous	Negative	Negative	Negative	Negative				
Clear cell PRCC	Positive, cup-like	Positive	Negative	Negative	Negative				
Chromophobe RCC, classic	Negative	Positive, cytoplasmic	Positive, membranous	Negative	Negative				
Epithelioid-AML MiTF-TFE tumors	Negative	Negative	Negative	Positive, cytoplasmic	Positive, cytoplasmic				
Xp11 family t(6;11)	Variable but focal Variable but focal	Negative Negative	Variable Negative	Positive (50%), cytoplasmic Positive, cytoplasmic	Negative Positive (always focal)				

9	CAIX	CK7	AMACR	Cathepsin-K	34βE12	TFE3/TFEE
ccRCC with papillary growth	Positive, membranous	Negative	Negative	Negative	Negative	Negative
PRCC "type I"	Negative	Positive	Positive	Negative	Negative	Negative
PRCC "type II"	Negative	\pm Positive	Positive	Negative	Negative	Negative
Clear cell PRCC	Positive, cup-like	Positive, diffuse	Negative	Negative	Negative	Negative
MiTF-TFE trans-assoc	Variable but focal	Negative	Positive	Positive (50%)	Negative	Positive*

Clear Cell Papillary RCC




- Tubulopapillary
- Clear cytoplasm
- Apically oriented nuclei



AMACR


Clear Cell Papillary RCC

CAIX




Complete Membranous Conventional clear cell RCC

Beware of false positive staining adjacent to necrosis



Clear Cell Papillary Renal Cell Carcinoma A Distinct Histopathologic and Molecular Genetic Entity

Stefano Gobbo, MD,*† John N. Eble, MD,* David J. Grignon, MD,* Guido Martignoni, MD,† Gregory T. MacLennan, MD,‡ Rajal B. Shah, MD,§ Shaobo Zhang, MD,* Matteo Brunelli, MD,† and Liang Cheng, MD*



Am J Surg Pathol • Volume 32, Number 8, August 2008

TABLE 2. Immunohistochemical Findings

	\frown		Antibodies	\frown	
Case No.	AMACR	CA IX	CD10	СК 7	TFE3
1	Neg	+ + +	Neg	$\overbrace{++}$	Neg
2	Neg	+ + +	Neg	+ + +	Neg
3	Neg	+ + +	Neg	+ + +	Neg
4	Neg	+ + +	-/+	+ + +	Neg
5a	Neg	+ + +	Neg	+ + +	Neg
5Ъ	Neg	+ + +	Neg	+ + +	Neg
5c	Neg	+ + +	Neg	+ + +	Neg

Neg indicates negative; -/+, 1% to 25% positive; +, 26% to 50% positive;

TABLE	1.	Clinico	pathologic	: Findings

Case No.	Age	Sex	Size (cm)	Fuhrman Grade	Stage	ESRD	Follow-up (mo)
1	64	W	1.6	G1	pT1	No	NED (24)
2	63	М	2.9	Gl	pT1	No	NED (26)*
3	64	М	4.2	G2	pT1	No	NED (1)
4	55	М	5	G1	\mathbf{p} T1	No	NED (48)
5	53	W	0.4; 1; 1.2	G2; G2;	pT1	Yes	NED (22)
				G2			

Clear Cell Papillary RCC




TABLE 3. Percentages of Nuclei With Different Numbers of Signals From Neoplastic Cells and Results for Chromosome 7, 17,
and Y

	CEP 7					CEI	CEP Y				
Case No.	1 Signal (%)	2 Signals (%)	≥3 Signals (%)	Result	1 Signal (%)	2 Signals (%)	≥3 Signals (%)	Result	0 Signal (%)	1 Signal (%)	Result
1	35	53	12	Disomic	40	55	5	Disomic			
2	33	65	2	Disomic	6	34	60	Trisomic	10	90	No loss
3	33	65	2	Disomic	38	56	6	Disomic	22	78	No loss
4	32	63	5	Disomic	26	71	3	Disomic	18	82	No loss
5a	27	66	7	Disomic	26	68	6	Disomic			
5Ъ	28	67	5	Disomic	38	51	11	Disomic	/		
5c	38	59	3	Disomic	29	63	8	Disomic	/		<u> </u>

 \smallsetminus

 \sim